Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

41. Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance

Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance Relative to SSRI users, SSRI–statin users have fewer psychiatric hospital contacts and no increase in suicidal behaviour or all-cause mortality | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please

2018 Evidence-Based Mental Health

42. Cognitive therapy for schizophrenia

Cognitive therapy for schizophrenia Cognitive therapy for schizophrenia Cognitive therapy for schizophrenia Leas B, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Leas B, Umscheid CA. Cognitive therapy for schizophrenia. Philadelphia: Center for Evidence-based Practice (CEP). 2018 Final publication URL Indexing Status Subject (...) indexing assigned by CRD MeSH Cognitive Therapy; Humans; Schizophrenia Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber 32018000158 Date abstract record published 16/04/2018 Health Technology Assessment (HTA) database Copyright © 2019

2018 Health Technology Assessment (HTA) Database.

43. Cost-effectiveness of cognitive–behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study (PubMed)

Cost-effectiveness of cognitive–behavioural therapy for sleep disorder added to usual care in patients with schizophrenia: the BEST study Sleep problems are pervasive in people with schizophrenia, but there are no clinical guidelines for their treatment. The Better Sleep Trial (BEST) concluded that suitably adapted cognitive-behavioural therapy (CBT) is likely to be highly effective, although its cost-effectiveness is unknown.To assess the potential cost-effectiveness of CBT for sleep (...) (95% CI -10 529 to 4736) and £1227 (95% CI -10 395 to 5361) lower costs from National Health Service and societal perspectives, respectively. The estimated value of collecting more information about the effects of the CBT on costs and QALYs was approximately £87 million.CBT for insomnia in people with schizophrenia is effective and potentially cost-effective. A larger trial is needed to provide clear evidence about its cost-effectiveness.Patients with schizophrenia have multiple complex health

Full Text available with Trip Pro

2018 BJPsych open

44. Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia

Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Discover Portal Discover Portal Uncertain benefit of adding amisulpiride to clozapine for treatment-resistant schizophrenia Published on 14 November 2017 doi: For adults with schizophrenia who continue to have symptoms despite treatment with the antipsychotic drug clozapine, adding amisulpride (another (...) particular drug. Amisulpride is often used in practice, but to date, there had not been much evidence on which to base this decision. Only 68 people with this severe form of schizophrenia were recruited instead of the expected 230, so the ability to detect any clinically significant differences between the groups is reduced. Share your views on the research. Why was this study needed? About 220,000 people in England and Wales have a diagnosis of schizophrenia. In 2007, approximately 30% of the total

2018 NIHR Dissemination Centre

45. Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City (PubMed)

Prevalence, factors and reasons associated with missed first appointments among out-patients with schizophrenia at the Federal Neuro-Psychiatric Hospital, Benin City Non-attendance to clinic appointments is associated with poorer treatment outcomes. There is a dearth of information about missed first clinic appointments among patients with schizophrenia in Nigeria.To determine the prevalence, correlates and reasons for missed first appointment among out-patients with schizophrenia (...) at the Federal Neuro-Psychiatric Hospital, Benin City, Nigeria.A cross-sectional descriptive study among 275 out-patients with schizophrenia, using the Mini International Neuro-Psychiatric Interview and the Brief Psychiatric Rating Scale.The prevalence of missed first appointment was 31%. Higher BPRS score was associated with missing the appointment. The main reasons for missed appointments were: forgetting the appointment date and patient's refusal to come to the clinic.Missed first out-patient clinic

Full Text available with Trip Pro

2018 BJPsych open

46. Selective noradrenaline reuptake inhibitors for schizophrenia. (PubMed)

Selective noradrenaline reuptake inhibitors for schizophrenia. Schizophrenia is frequently a chronic and disabling illness with a heterogeneous range of symptoms. The positive symptoms usually respond to antipsychotics but the cognitive and negative symptoms of schizophrenia are difficult to treat with conventional antipsychotics and significantly impact on quality of life and social outcomes. Selective noradrenaline reuptake inhibitors (NRIs) increase prefrontal dopamine and noradrenaline (...) levels without significantly affecting subcortical dopamine levels, making them an attractive candidate for treating cognitive and negative symptoms.To investigate the effects of selective noradrenaline reuptake inhibitors (NRIs), compared with a placebo or control treatment, for people with schizophrenia.We searched the Cochrane Schizophrenia Group's Trials Register (up to 7 February 2017) which is based on regular searches of MEDLINE, Embase, CINAHL, BIOSIS, AMED, PubMed, PsycINFO, and registries

Full Text available with Trip Pro

2018 Cochrane

47. Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics (PubMed)

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics The objective of this study was to compare persistence, costs, and healthcare resource utilization in patients with schizophrenia and cardiometabolic comorbidities treated with once-monthly paliperidone palmitate or an oral atypical antipsychotic.Medicaid data from six states (07/2009-03/2015) were used to identify (...) adults with schizophrenia and cardiometabolic comorbidities initiated on once-monthly paliperidone palmitate or an oral atypical antipsychotic (index date) on 01/2010 or after. Persistence to index medication at 12 months (no gap ≥ 90 days) was compared between patients taking once-monthly paliperidone palmitate and an oral atypical antipsychotic using Chi-squared tests. The 12-month post-index healthcare costs and healthcare resource utilization were compared using multivariate ordinary least

Full Text available with Trip Pro

2018 Drugs - real world outcomes

48. Transcranial Magnetic Stimulation for Major Depression and Schizophrenia

Transcranial Magnetic Stimulation for Major Depression and Schizophrenia Transcranial Magnetic Stimulation for Major Depression and Schizophrenia An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017 An Evidence Check rapid review brokered by the Sax Institute for the NSW Ministry of Health. August 2017. This report was prepared by: Ma N, Atukorale Y, Duncan J, Marlow N, Cameron A Research and Evaluation, incorporating ASERNIP-S, Royal (...) www.saxinstitute.org.au knowledge.exchange@saxinstitute.org.au Phone: +61 2 91889500 Suggested Citation: Ma N, Atukorale Y, Marlow N, Duncan J, Cameron A (2017) Transcranial Magnetic Stimulation for major depression and schizophrenia: an Evidence Check brokered by the Sax Institute (www.saxinstitute.org.au) for the NSW Ministry of Health, 2017. Disclaimer: This Evidence Check Review was produced using the Evidence Check methodology in response to specific questions from the commissioning agency. It is not necessarily

2018 Sax Institute Evidence Check

49. Pharmacological interventions: L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia

Pharmacological interventions: L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here L-methylfolate cannot yet be recommended as an add-on treatment in schizophrenia Article Text Commentary Pharmacological interventions L-methylfolate cannot yet be recommended as an add-on treatment

2018 Evidence-Based Mental Health

50. Schizophrenia

Schizophrenia Schizophrenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Schizophrenia Last reviewed: February 2019 Last updated: June 2018 Summary An illness characterised by a co-occurrence of at least two of the following symptoms: hallucinations, delusions, disorganised speech, disorganised/catatonic behaviour, or negative symptoms occurring for a significant period of time during a 1-month period (...) and delusions to frank psychosis. Initially, patients are usually referred by family members. As the illness progresses, patients tend to self-refer or are brought in by a case manager or law enforcement officer. Antipsychotic therapy and psychosocial interventions are effective for most patients, but to varying degrees. Suicidal tendency is one of the most dangerous complications. The lifetime risk of suicide is around 5%. The risk is highest at the onset of the illness. Definition Schizophrenia

2018 BMJ Best Practice

51. N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) G1001C polymorphism and susceptibility to schizophrenia: A meta-analysis.

N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) G1001C polymorphism and susceptibility to schizophrenia: A meta-analysis. A comprehensive literature search was conducted to identify all case-control studies investigating the association between GRIN1 G1001C polymorphism and schizophrenia susceptibility (MIM: 138249; dbSNP: rs 11146020). A total of 6 eligible studies (including 1639 schizophrenia cases and 1489 controls) were identified for the meta-analysis. Including all studies (...) , there was significant heterogeneity between studies. In overall the GC (OR=1.00, 95 % CI: 0.0.85-1.19) and CC (OR=1.09, 95 % CI: 0.67-1.79) genotypes were not associated with schizophrenia risk compared with the GG genotype. In one study patients were diagnosed using DSM-IIIR criteria and in another study the genotypic frequencies of control subjects showed significant deviation from the expected frequencies according to the Hardy-Weinberg equilibrium. After excluding these studies from the meta-analysis

2017 EXCLI journal

52. Zuclopenthixol dihydrochloride for schizophrenia. (PubMed)

Zuclopenthixol dihydrochloride for schizophrenia. Oral zuclopenthixol dihydrochloride (Clopixol) is an anti-psychotic treatment for people with psychotic symptoms, especially those with schizophrenia. It is associated with neuroleptic malignant syndrome, a prolongation of the QTc interval, extra-pyramidal reactions, venous thromboembolism and may modify insulin and glucose responses.To determine the effects of zuclopenthixol dihydrochloride for treatment of schizophrenia.We searched (...) the Cochrane Schizophrenia Group's Trials Register (latest search 09 June 2015). There were no language, date, document type, or publication status limitations for inclusion of records in the register.All randomised controlled trials (RCTs) focusing on zuclopenthixol dihydrochloride for schizophrenia. We included trials meeting our inclusion criteria and reporting useable data.We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI

Full Text available with Trip Pro

2017 Cochrane

53. Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses (PubMed)

Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses Efficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bipolar I disorder (Clinicaltrials.gov: NCT00628589, NCT00721955).To examine the five individual items (...) comprising the PANSS-EC and the percentage of patients achieving a clinical response (reduction of ≥40%) in PANSS-EC (Response-40) for these two studies.Response-40 was examined at the primary end-point (2 h) and over time.Response-40 and each PANSS-EC item score were statistically significant v. placebo at 2 h and at each assessment time point for both doses.Inhaled loxapine produced rapid improvement in agitated patients with schizophrenia or bipolar I disorder, achieving Response-40 at the first

Full Text available with Trip Pro

2017 BJPsych open

54. Individual differences in schizophrenia (PubMed)

Individual differences in schizophrenia Whether there are distinct subtypes of schizophrenia is an important issue to advance understanding and treatment of schizophrenia.To understand and treat individuals with schizophrenia, the aim was to advance understanding of differences between individuals, whether there are discrete subtypes, and how first-episode patients (FEP) may differ from multiple episode patients (MEP).These issues were analysed in 687 FEP and 1880 MEP with schizophrenia using (...) the Positive and Negative Syndrome Scale for (PANSS) schizophrenia before and after antipsychotic medication for 6 weeks.The seven Negative Symptoms were correlated with each other and with P2 (conceptual disorganisation), G13 (disturbance of volition), and G7 (motor retardation). The main difference between individuals was in the cluster of seven negative symptoms, which had a continuous unimodal distribution. Medication decreased the PANSS scores for all the symptoms, which were similar in the FEP

Full Text available with Trip Pro

2017 BJPsych open

55. Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran (PubMed)

Morphology of the corpus callosum and schizophrenia: A case-control study in Kashan, Iran Corpus Callosum (CC) plays a significant role in hemispheric communication and in lateralized brain function and behaviors. Structural abnormalities in the corpus callosum of schizophrenic patients were reported. However, previous studies regarding the relationship between morphology of CC in patients with schizophrenia and healthy people are controversial.To evaluate the morphological differences (...) of the CC between patients with chronic schizophrenia and healthy people and to examine the relationship between the characteristics of the CC and schizophrenia severity.This cross-sectional study was conducted on 63 patients with chronic schizophrenia (the case group) referred to Kargarnezhad Psychiatric Hospital in Kashan, Iran, and 63 healthy people (the control group) between January 2013 and December 2014. All participants underwent brain magnetic resonance imaging. Shape, anteroposterior length

Full Text available with Trip Pro

2017 Electronic physician

56. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. (PubMed)

Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Delivering the diagnosis of a serious illness is an important skill in most fields of medicine, including mental health. Research has found that communication skills can impact on a person's recall and understanding of the diagnosis, treatment options and prognosis. People may feel confused and perplexed when information about their illness is not communicated properly. Sharing information (...) diagnoses to people; however, little is known specifically for delivering a diagnosis of schizophrenia.To evaluate evidence from randomised controlled trials (RCTs) for the efficacy of different communication strategies used by clinicians to inform people about the diagnosis and outcome of schizophrenia compared with treatment as usual and to compare efficacy between different communication strategies.On 22 June 2015 and 29 June 2016, we searched the Cochrane Schizophrenia Group's Study-Based Register

Full Text available with Trip Pro

2017 Cochrane

57. A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina (PubMed)

A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina Schizophrenia is considered a serious mental disorder that affects over 21 million people worldwide, and is associated with disability that frequently affects the patient's educational and working performance. In Argentina, two of the most widely used antipsychotics in the treatment of this disorder are haloperidol and risperidone. Both are provided free (...) to patients without health coverage in public healthcare facilities. In this paper we seek to review the clinical and economic benefits of prescribing psychotropic therapies based on haloperidol (a first-generation antipsychotic that is part of the butyrophenone group of drugs) versus risperidone [an atypical or second-generation antipsychotic (neuroleptic) drug] in adult patients who have been diagnosed with schizophrenia. To achieve this objective, an exhaustive search of relevant articles published

Full Text available with Trip Pro

2017 PharmacoEconomics open

58. Obesity in individuals with schizophrenia: a case controlled study in Scotland (PubMed)

Obesity in individuals with schizophrenia: a case controlled study in Scotland Despite extensive clinical concern about rates of obesity in patients with schizophrenia, there is little evidence of the extent of this problem at a population level.To estimate levels of obesity in a national population sample by comparing patients with schizophrenia with matched controls.We calculated levels of obesity for each patient with schizophrenia from the national Primary Care Clinical Informatics Unit (...) database (n=4658) matched with age, gender and neighbourhood controls.We demonstrated a significant increased obesity hazard for the schizophrenia group using Cox regression analysis, with odds ratio (OR) of 1.94 (95% CI 1.81-2.10) (under the assumption of missing body mass index (BMI) indicating non-obesity) and OR=1.68 (95% CI 1.55-1.81) where no assumptions were made for missing BMI data.People with schizophrenia are at increased risk of being obese compared with controls matched by age, gender

Full Text available with Trip Pro

2017 BJPsych open

59. Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia

Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia This study evaluated rates of all-cause mortality and self-harm in association with clozapine treatment in individuals with treatment-resistant schizophrenia.A population-based cohort of 2,370 individuals with treatment-resistant schizophrenia after Jan. 1, 1996, was followed until death, first episode of self-harm, emigration, or June 1, 2013. Time to all-cause death and time to first episode of self (...) : 1.45, 95% CI: 0.86-2.45). Excess mortality was observed in the year after clozapine discontinuation (hazard ratio: 2.65, 95% CI: 1.47-4.78). The rate of self-harm was higher for nonclozapine antipsychotics than for clozapine (hazard ratio: 1.36, 95% CI: 1.04-1.78).The results demonstrate a nearly twofold higher mortality rate among individuals with treatment-resistant schizophrenia not treated with clozapine compared with clozapine-treated individuals. Furthermore, the results suggest a harmful

Full Text available with Trip Pro

2017 EvidenceUpdates

60. Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth (PubMed)

Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices (...) in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders.A systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings

Full Text available with Trip Pro

2017 CPG Infobase